Sanofi

Pieris Pharmaceuticals Gmbh

Carsten Corvey

Christian Lange

Jochen Kruip

Andrea Allersdorfer

Christine Rothe

Marlon Hinner

Ercole Rao

Alexander Wiedenmann

Kristian Hobolt Jensen

Bradley Lunde

Laurent Fraisse

Heike Stump

Michael Mourez

Astrid Rey

Martin Hülsmeyer

Nicolas Baurin

Bernhard Calandra

Nathalie Karst

Vincent Mikol

Ingo Focken

Gary J Nabel

Christian Beil

Tarik Dabdoubi

Zhi-Yong Yang

Lan Wu

Jochen Beninga

Edward Seung

Wulf Dirk Leuschner

Francis Blanche

Beatrice Cameron

Ronnie Rong Wei

Martin Lorenz

Christian Engel

Anke Steinmetz

Danxi Li

Thomas Langer

Hans-Falk Rasser

Katja Kroll

Peter Wonerow

Chirstian Biel

Dorothea Rat

Peter Florian

Bernard Calandra

Juergen Schaefer

Thomas Stuedemann

Béatrice Cameron

Horst Blum

Stéphanie Decary

David Papin

Ronnie Wei

Rao Ercole

The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific and/or trivalent binding proteins

The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth ofand/or to prevent or treatbiofilm infection as well as diseases or disorders associated withbiofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.

Fusion molecules

The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.

Proteins specific for pyoverdine and pyochelin

The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used.

Antagonist antibodies and their fab fragments against GPVI and uses thereof

The present invention relates to a peptide or peptide complex binding to &#x3b1;2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting &#x3b1;2 integrin and a screening method.

Peptide or peptide complex binding to ALPHA2 integrin and methods and uses involving the same

The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.

Dual variable region antibody-like binding proteins having cross-over binding region orientation

Growing community of inventors

Frankfurt am Main, Germany

Carsten Corvey